Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78

Oncology Reports

Volumn 31, Issue 6, 2014, Pages 2525-2534

  Li, Wei ^a   Wang, Wei ^b   Dong, Hong ^a   Li, Yan ^a   Li, L I ^a   Han, Linfei ^c   Han, Zhiqiang ^a   Wang, Shixuan ^a   Ma, Ding ^a   Wang, Hui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

Ataxia telangiectasia mutated; Cell senescence; Cisplatin; Drug resistance; GRP78; Ovarian cancer

Indexed keywords

BETA GALACTOSIDASE; CALCIUM ION; CISPLATIN; CYCLIN DEPENDENT KINASE 1; GLUCOSE REGULATED PROTEIN 78; HETEROCHROMATIN PROTEIN 1; HETEROCHROMATIN PROTEIN 1 GAMMA; PACLITAXEL; PROTEIN P53; UNCLASSIFIED DRUG; HEAT SHOCK PROTEIN; HETEROCHROMATIN-SPECIFIC NONHISTONE CHROMOSOMAL PROTEIN HP-1; MOLECULAR CHAPERONE GRP78; NONHISTONE PROTEIN;

A2780 CELL LINE; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C13K CELL LINE; CALCIUM TRANSPORT; CANCER CELL; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CDC2 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; ENDOPLASMIC RETICULUM; ENZYME MECHANISM; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; OVARY TUMOR; P21 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; TUMOR SUPPRESSOR GENE; AGING; APOPTOSIS; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

AGING; APOPTOSIS; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; OVARIAN NEOPLASMS;

EID: 84902154472     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3147     Document Type: Article

References (38)

1. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63: 11-16, 2003.
2. Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S and Ma D: Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol Oncol 97: 413-421, 2005. (Pubitemid 40614884)
3. Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97: 26-34, 2005. (Pubitemid 40403670)
4. Gifford G, Paul J, Vasey PA, Kaye SB and Brown R: The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10: 4420-4426, 2004. (Pubitemid 38878884)
5. Williams J, Lucas PC, Griffith KA, et al: Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96: 287-295, 2005. (Pubitemid 40127123)
6. Roninson IB: Tumor cell senescence in cancer treatment. Cancer Res 63: 2705-2715, 2003.
7. Elmore LW, Xu Di, Dumur C, Holt SE and Gewirtz DA: Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res 11: 2637-2643, 2005. (Pubitemid 40569464)
8. Lee BY, Han JA, Im JS, et al: Senescence-associated β-galactosidase is lysosomal β-galactosidase. Aging Cell 5: 187-195, 2006.
9. Bartkova J, Rezaei N, Liontos M, et al: Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444: 633-637, 2006. (Pubitemid 44864442)
10. te Poele RH, Okorokov AL, Jardine L, Cummings J and Joel SP: DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62: 1876-1883, 2002. (Pubitemid 34408516)
11. INK4a contributes to the outcome of cancer therapy. Cell 109: 335-346, 2002.
12. Roninson IB: Tumour senescence as a determinant of drug response in vivo. Drug Resist Updat 5: 204-208, 2002.
13. INK4a. Oncol Res 16: 479-488, 2007.
14. Lee AS: The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 26: 504-510, 2001.
15. Ranganathan AC, Zhang L, Adam AP and Aguirre-Ghiso JA: Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 66: 1702-1711, 2006. (Pubitemid 43259955)
16. Fu Y, Li J and Lee AS: GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen-starvation induced apoptosis. Cancer Res 67: 3734-3740, 2007. (Pubitemid 46762159)
17. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ and Lee AS: Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 278: 20915-20924, 2003. (Pubitemid 36806399)
18. Ermakova SP, Kang BS, Choi BY, et al: (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 66: 9260-9269, 2006. (Pubitemid 44521148)
19. Davidson DJ, Haskell C, Majest S, et al: Kringle 5 of human plasminogen induces apoptosis of endothelial and tumour cells through surface-expressed glucose-regulated protein 78. Cancer Res 65: 4663-4672, 2005. (Pubitemid 40740802)
20. Mandic A, Hansson J, Linder S and Shoshan MC: Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278: 9100-9106, 2003. (Pubitemid 36800390)
21. Lee H K, Xiang CL, Cazacu S, et al: GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis. Neuro Oncol 10: 236-243, 2008.
22. Jiang CC, Mao ZG, Avery-Kiejda K, Wade M, Hersey P and Zhang XD: Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis 30: 197-204, 2009.
23. Zu K, Bihani T, Lin A, Park YM, Mori K and Ip C: Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene 25: 546-554, 2006. (Pubitemid 43164465)
24. Tate S, Hirai Y, Takeshima N and Hasumi K: CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol 96: 143-149, 2005. (Pubitemid 39612429)
25. Wang W, Wang S, Song X, et al: The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis. Gynecol Oncol 105: 571-577, 2007. (Pubitemid 46734183)
26. Hawkins LK, Johnson L, Bauzon M, et al: Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. Gene Ther 8: 1123-1131, 2001. (Pubitemid 32776385)
27. Fernandez PM, Tabbara SO, Jacobs LK, et al: Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 59: 15-26, 2000. (Pubitemid 30153894)
28. Koomägi R, Mattern J and Volm M: Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas. Anticancer Res 19: 4333-4336, 1999.
29. Taylor DD, Gercel-Taylor C and Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 115: 112-120, 2009.
30. Arap MA, Lahdenranta J, Mintz PJ, et al: Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6: 275-284, 2004. (Pubitemid 39222040)
31. Zhou H, Zhang Y, Fu Y, Chan L and Lee AS: Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK). J Biol Chem 286: 25687-25696, 2011.
32. Petroulakis E, Parsyan A, Dowling RJ, et al: p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell 16: 439-446, 2009.
33. Gannon HS, Donehower LA, Lyle S and Jones SN: Mdm2-p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin. Dev Biol 353: 1-9, 2011.
34. Vaziri H, West MD, Allsopp RC, et al: ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J 16: 6018-6033, 1997. (Pubitemid 27427297)
35. Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414, 2009.
36. Shen H and Maki CG: Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem 285: 23105-23114, 2010.
37. Roberson RS, Kussick SJ, Vallieres E, Chen SY and Wu DY: Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 65: 2795-2803, 2005. (Pubitemid 40490082)
38. Giorgi C, Ito K, Lin HK, et al: PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 330: 1247-1251, 2010.